Affimed Announces Pricing of Upsized $90 Million Public Offering of Common SharesApril 13, 2022
Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the pricing of its previously announced public offering of 22,500,000 of its common shares at a public offering price of $4.00 per common share.
In addition, Affimed has granted the underwriters a 30-day over-allotment option to purchase up to 3,375,000 common shares at the public offering price less underwriting discounts. After deducting the underwriting discounts, the net proceeds of the public offering are expected to be $84.6 million.
The offering is expected to close on or about April 18, 2022, subject to customary closing conditions. Jefferies LLC, SVB Leerink, Truist Securities, Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers and Berenberg Capital Markets LLC is acting as a co-manager of the offering. A shelf registration statement relating to these securities filed with the Securities and Exchange Commission (the “SEC”) was declared effective by the SEC on April 6, 2022. The offering will be made only by means of a prospectus and prospectus supplement. A preliminary prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available at the SEC’s website located at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC.